Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.

Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3972-7. Unique Identifier : AIDSLINE MED/96210576
McElrath MJ; Corey L; Greenberg PD; Matthews TJ; Montefiori DC; Rowen L; Hood L; Mullins JI; Department of Medicine, University of Washington School of; Medicine, Seattle 98195, USA.

Abstract: With efforts underway to develop a preventive human immunodeficiency virus type 1 (HIV-1) vaccine, it remains unclear which immune responses are sufficient to protect against infection and whether prior HIV-1 immunity can alter the subsequent course of HIV-1 infection. We investigated these issues in the context of a volunteer who received six HIV-1LAI envelope immunizations and 10 weeks thereafter acquired HIV-1 infection through a high-risk sexual exposure. In contrast to nonvaccinated acutely infected individuals, anamnestic HIV-1-specific B- and T-cell responses appeared within 3 weeks in this individual, and neutralizing antibody preceded CD8+ cytotoxic responses. Despite an asymptomatic course and an initial low level of detectable infectious virus, a progressive CD4+ cell decline and dysfunction occurred within 2 years. Although vaccination elicited immunity to HIV-1 envelope, which was recalled upon HIV-1 exposure, it was insufficient to prevent infection and subsequent immunodeficiency.

Keywords: Adult Amino Acid Sequence *AIDS Vaccines B-Lymphocytes/IMMUNOLOGY Case Report Comparative Study CD4-Positive T-Lymphocytes/IMMUNOLOGY CD8-Positive T-Lymphocytes/IMMUNOLOGY Gene Products, env/BIOSYNTHESIS/CHEMISTRY/*IMMUNOLOGY Homosexuality, Male Human HIV Antibodies/*BLOOD HIV Infections/*IMMUNOLOGY *HIV Seropositivity *HIV-1 Male Molecular Sequence Data Protein Precursors/IMMUNOLOGY Risk-Taking Smallpox Vaccine Support, U.S. Gov't, Non-P.H.S. Support, U.S. Gov't, P.H.S. T-Lymphocytes/IMMUNOLOGY Time Factors *Vaccines, Synthetic JOURNAL ARTICLE
960930
M9690893

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .